Phase 3 N=92 Efficacy and Safety of Zenoctil in Reducing Body Weight
Overweight
Primary: Change in Mean Body Weight (kg) — -2.26; -0.56 kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=39 Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic
Infectious Disease
Primary: Treatment-associated Change in S. Aureus Colonization During a Typical 10-hour Work Day — -99.8; -13.5 Percent change in colonization — p=<0.01
Phase 2 N=109 Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Primary: Change From Baseline to Month 3 in Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS)…
Phase 2 N=11 Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Breast Cancer
Primary: Maximum-tolerated Dose of Bendamustine Hydrochloride (Phase I) — 120 mg/m^2
Phase 3 N=140 A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)
Facial Wrinkles at the Nasolabial Folds
Primary: Change From Baseline in the Blinded Evaluator's Assessment of Nasolabial Fold (NLF) Wrinkle Severity at Week 24 — 1.8; 1.8 Units on a scale
N/A N=200 Amyotrophic Lateral Sclerosis Registry Rhineland-Palatinate
Amyotrophic Lateral Sclerosis
Primary: Death — 134 participants
N/A N=513 Perioperative Antibiotic Choices for Surgical Prophylaxis in Penicillin-allergic Pediatric Patients
Penicillin Allergy
Primary: Number of Subjects With Antibiotic Related Adverse Event — 12 participants
Phase 2 N=57 Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer
Prostate Cancer
Primary: PSA Response — 56 percentage of participants
N/A N=34 Youth Smoking Cessation: Therapy +/- "The Patch"
Smoking
Primary: Acceptance of Nicotine Replacement Therapy — 26 participants
Phase 4 N=23 Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
Parkinson's Disease · Gait Impairment
Primary: The Primary Outcome Measure Was Change in a Gait Stride Length Between Groups at 12 and 27 Weeks. — 107.66; 112.29; 103.35 centimeters
Phase 4 N=1,829 How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
Acute ST Elevation Myocardial Infarction
Primary: Major Adverse Cardiac Events (MACE) in Terms of the Incidence of All Cause Mortality, Cerebrovascular Accident, Re-infarction and Additional Unplanned Target Lesion…
Phase 2 N=14 NMDA Receptors in Motor Learning in Humans
Stroke
Primary: Grip Strength of Affected Hand — 3.95; 5.72; 4.90; 8.44 Newton
Phase 3 N=1,692 Multi-arm Intervention Diabetes Adherence Study
Diabetes
Primary: Glycated Hemoglobin Levels — 7.88; 7.91; 7.79 Percent — p=0.763
Phase 1 N=55 Open Label Pharmacokinetic Study of OZ439 and Piperaquine on Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in Healthy Volunteers
Malaria
Primary: OZ439 Cmax — 1300; 1490; 1240; 1120 ng/mL
Phase 2 N=19 Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
Acinar Cell Adenocarcinoma of the Pancreas · Duct Cell Adenocarcinoma of the Pancreas · Recurrent Pancreatic Cancer
Primary: Response Rate of at Least 30% — 0 participants